Ambagon is discovering and developing small molecule cancer drugs that stabilize the direct interaction of oncogenic proteins with the 14-3-3 class of adaptor proteins.
Ambagon’s platform approach will open opportunities to address major unmet clinical needs beyond oncology.
Location: United States, California, San Francisco
Employees: 11-50
Total raised: $84.91M
Founded date: 2020
Investors 5
| Date | Name | Website |
| - | Mission Bi... | missionbio... |
| 09.01.2022 | RA Capital... | racap.com |
| 07.09.2022 | MRL Ventur... | mrlv.com |
| - | Droia Onco... | droiaventu... |
| - | For Good V... | forgoodven... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.01.2022 | - | $84.91M | - |
Mentions in press and media 3
| Date | Title | Description | Source |
| 08.01.2022 | US-based biotech startup Ambagon Therapeutics raises USD 85 ... | Ambagon Therapeutics, a biotechnology company pioneering methods to unlock intrinsically disordered ... | vcbay.news... |
| 07.01.2022 | Biotech startup Ambagon Therapeutics raises €75.1M from Amst... | Ambagon Therapeutics is a biotechnology company that is developing cancer molecule therapeutics. The... | siliconcan... |
| 07.01.2022 | Ambagon Therapeutics Raises $85M in Series A Funding | Ambagon Therapeutics, a San Francisco CA-based biotechnology company, raised $85M in Series A fundin... | finsmes.co... |